We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Show more
Serum 4-Hydroxynonenal (4-HNE) levels are significantly increased in ALS patients- the higher the 4-HNE level, the faster the progression and shorter the survival; Serum 4-HNE levels are...
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that...
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that...
Additional 4-HNE (4-hydroxynonenal) biomarker data to highlight the correlation of bulbar and limb onset ALS (Amyotrophic Lateral Sclerosis) to 4-HNE levels Coya Therapeutics, Inc. (Nasdaq: COYA...
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a...
Coya’s Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader Coya Therapeutics, Inc. (Nasdaq:...
4-Hydroxynonenal (4-HNE) levels strongly correlate with rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and survival of patients from onset and diagnosis to death (91.7...
Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines significantly increased in FTD patients COYA 302, Coya’s lead...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 2.01660735469 | 8.43 | 9.22 | 7.81 | 63643 | 8.26673063 | CS |
4 | -1.37 | -13.741223671 | 9.97 | 10.23 | 7.81 | 59182 | 8.90756639 | CS |
12 | 2.4 | 38.7096774194 | 6.2 | 10.6899 | 5.83 | 103814 | 9.06450935 | CS |
26 | 3.83 | 80.2935010482 | 4.77 | 10.6899 | 4.4 | 73555 | 8.13302622 | CS |
52 | 3.87 | 81.8181818182 | 4.73 | 10.6899 | 3.21 | 86234 | 6.32204563 | CS |
156 | 3.85 | 81.0526315789 | 4.75 | 10.6899 | 3.21 | 70677 | 6.17723805 | CS |
260 | 3.85 | 81.0526315789 | 4.75 | 10.6899 | 3.21 | 70677 | 6.17723805 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions